Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination

Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately... Am J Cardiovasc Drugs 2011; 11 (5): 327-333 ORIGINAL RESEARCH ARTICLE 1175-3277/11/0005-0327/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination A Placebo-Controlled Study 1 2 3 4 5 W. Drummond, Y.M. Sirenko, E. Ramos, I. Baek and D.L. Keefe 1 Renaissance Clinical Research and Hypertension Center, Dallas, TX, USA 2 Institute of Cardiology, Kyiv, Ukraine 3 Department of Medicine, University of Seville, Seville, Spain 4 Novartis Pharma AG, Basel, Switzerland 5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Abstract Background: Hypertension frequently coexists with diabetes mellitus, resulting in increased cardiovascular risk. Thus, BP control is crucial in decreasing morbidity and mortality in this difficult-to-treat patient population. Objective: The objective of this study was to evaluate the efficacy and safety of aliskiren in hypertensive patients with diabetes not adequately responsive to the combination of valsartan and hydrochlorothiazide (HCT). Methods: After a 1- to 4-week washout period, patients with a mean sitting diastolic BP (msDBP) ‡95 mmHg were treated with valsartan 160 mg for 2 weeks followed by valsartan/HCT 160 mg/25 mg for an additional 4 weeks (single-blind active run-in period). Patients whose msDBP http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination

Loading next page...
 
/lp/springer-journals/aliskiren-as-add-on-therapy-in-the-treatment-of-hypertensive-diabetic-8KIGTUJdGW

References (38)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Adis Data Information BV
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/11591970-000000000-00000
pmid
21846154
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs 2011; 11 (5): 327-333 ORIGINAL RESEARCH ARTICLE 1175-3277/11/0005-0327/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination A Placebo-Controlled Study 1 2 3 4 5 W. Drummond, Y.M. Sirenko, E. Ramos, I. Baek and D.L. Keefe 1 Renaissance Clinical Research and Hypertension Center, Dallas, TX, USA 2 Institute of Cardiology, Kyiv, Ukraine 3 Department of Medicine, University of Seville, Seville, Spain 4 Novartis Pharma AG, Basel, Switzerland 5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Abstract Background: Hypertension frequently coexists with diabetes mellitus, resulting in increased cardiovascular risk. Thus, BP control is crucial in decreasing morbidity and mortality in this difficult-to-treat patient population. Objective: The objective of this study was to evaluate the efficacy and safety of aliskiren in hypertensive patients with diabetes not adequately responsive to the combination of valsartan and hydrochlorothiazide (HCT). Methods: After a 1- to 4-week washout period, patients with a mean sitting diastolic BP (msDBP) ‡95 mmHg were treated with valsartan 160 mg for 2 weeks followed by valsartan/HCT 160 mg/25 mg for an additional 4 weeks (single-blind active run-in period). Patients whose msDBP

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Aug 17, 2012

There are no references for this article.